US Supreme Court to hear Amgen-Sandoz biosimilars patent dance case
The dispute between Amgen and Sandoz over aspects of the so-called patent dance outlined in the Biologics Price Competition and Innovation Act was granted cert by the US Supreme Court
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: